Clinical Trials Directory

Trials / Completed

CompletedNCT01785784

Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn

Phase IV Clinical Trial of rhGM-CSF Hydro-gel for Topical Application on Deep 2nd Partial Thickness Burn

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2,510 (actual)
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
3 Years
Healthy volunteers
Not accepted

Summary

This was a multicenter, randomized, phase Ⅳ study, to investigate the extensive efficacy and safety of Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor Hydro-gel for Topical Application (rhGM-CSF Gel) on deep 2nd burn. There are two parts of the phase Ⅳstudy, the first part was a multicenter, randomized, reference controlled study, all the subjects were randomized into two groups, test group (rhGM-CSF Gel) and control group (iodophor gauze), totally 358 deep 2nd burned patients were enrolled in first part of the study, 177 cases were enrolled in test group and 181 cases were enrolled in reference control group. In the test group, after the patients were enrolled in the group, clean the wound surface regularly and wash with normal saline, spread the test drug on the wound surface, bandaging with sterilized vaseline gauze, change the drug product every two or one day according to the effusion. In the reference control group, after the patients were enrolled in the group, clean the wound surface regularly and wash with normal saline, bandaging with iodophor gauze, change the drug product every two or one day according to the effusion. Whole treatment were lasted till the wound surface was healing completely, if it is not recovered in 4 weeks, calculate and record the healing rate. The secondary part of the study was a multicenter, open study, to investigate the safety of rhGM-CSF on deep 2nd burn patients. Totally 2329 patients were enrolled in this part of the study.

Conditions

Interventions

TypeNameDescription
DRUGrhGM-CSF Gel

Timeline

Start date
2010-11-01
Primary completion
2012-04-01
Completion
2012-07-01
First posted
2013-02-07
Last updated
2013-02-07

Source: ClinicalTrials.gov record NCT01785784. Inclusion in this directory is not an endorsement.